Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: GlobeNewswire
Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potentialBroadens development pipeline with an adenovirus 4/7 vaccine funded by the DoD for military requirements as well as other programs addressing emerging infectious diseases for both commercial and government marketsExpands sales capabilities with the addition of global specialty salesforce and marketing and distribution partners focused on the travelers marketEstablishes international manufacturing footprint and provides opportunities for growth of CDMO business with European-based cGMP biologics facilitiesAll-cash transaction of $270 millionExpected to generate revenues of $70 million to $90 million in 2019 and be accretive by year-end 2019 GAITHERSBURG, Md., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect a
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- FDA approves Amneal's generic version of OTC Narcan [Seeking Alpha]Seeking Alpha
- Ascend Hires Scott Law as COO and Continues Strengthening Foundation [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024GlobeNewswire
- Institutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year losses [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 3/6/24 - Miss
EBS
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- EBS's page on the SEC website